Elevance Health, Inc. (ELV) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Elevance Health is a leading U.S. health insurer serving approximately 45.6 million medical members across Individual, Employer Group, Medicaid, and Medicare markets. The company operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The filing reflects the impact of recent acquisitions (Centers and CareBridge) and ongoing regulatory changes, including the "One Big Beautiful Bill Act" signed in July 2025.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) | Change |
|---|---|---|---|
| Total Operating Revenue | $98,186 million | $85,496 million | +14.8% |
| Net Income | $3,928 million | $4,550 million | -13.7% |
| Shareholders' Net Income | $3,926 million | $4,546 million | -13.6% |
| Diluted EPS | $17.33 | $19.44 | -10.9% |
| Operating Cash Flow | $3,071 million | $2,425 million | +26.6% |
| Total Assets | $121,938 million | $116,889 million | +4.3% |
| Total Debt | $29,826 million | $30,867 million | -3.4% |
| Debt-to-Capital Ratio | 40.8% | 43.0% | -220 bps |
| Benefit Expense Ratio | 87.7% | 85.9% | +180 bps |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 14.8% year-over-year, driven by premium rate increases in the Health Benefits segment, growth in Medicare Advantage and Individual ACA membership, and recent acquisitions. This was partially offset by Medicaid membership attrition due to eligibility redeterminations.
- Profitability Decline: Net income decreased 13.7% primarily due to a decline in operating gain within the Health Benefits segment (driven by medical cost trends exceeding premium rates in Medicaid and ACA plans) and increased net losses on financial instruments ($595 million vs. $246 million in 2024).
- Segment Performance:
- Health Benefits: Operating gain decreased 14.8% to $3,777 million due to inadequate rates in Medicaid and ACA plans relative to medical cost trends.
- Carelon Services: Operating gain surged 78.9% to $891 million, driven by the acquisition of CareBridge and improved performance in post-acute and behavioral health services.
- CarelonRx: Operating gain increased 11.6% to $1,138 million due to higher prescription volume.
- Investment Losses: Net losses on financial instruments increased significantly, largely due to higher losses on other invested assets, partially offset by lower losses from fixed maturity securities sales.
Guidance, Outlook, and Risks
- Regulatory Impact: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces changes to Medicaid eligibility, work requirements, and provider taxes, with most provisions effective in 2027-2028. The company anticipates potential revenue impacts from increased CMS Risk Adjustment Data Validation (RADV) audits.
- Star Ratings: 2025 Star Ratings (released Oct 2024) show a decline in the percentage of members in 4.0+ Star plans (38% vs. 53% in 2024). Management expects this to reduce 2026 operating revenue by approximately $183 million, though they plan to mitigate the impact on net income through cost efficiencies and contract diversification.
- Medical Cost Trends: Elevated medical cost trends persist, particularly in Medicaid and Individual ACA markets, driven by higher member acuity and utilization following the end of the public health emergency.
- Litigation: A Final Fairness Hearing is scheduled for July 29, 2025, regarding the Blue Cross Blue Shield Antitrust Litigation Provider Settlement. Elevance's estimated portion of the settlement is $666 million, which was accrued in September 2024.
Key Investor Verification Points
- Medical Cost Trend Sustainability: Verify if premium rate increases in Medicaid and ACA plans are sufficient to cover the elevated medical cost trends driving the decline in Health Benefits operating margin.
- Investment Portfolio Performance: Assess the drivers of the $595 million net loss on financial instruments and the potential for continued volatility in "other invested assets."
- Star Rating Mitigation: Monitor management's execution of strategies to offset the projected $183 million revenue reduction from lower Medicare Advantage Star Ratings in 2026.
- Regulatory Implementation: Track the implementation timeline and financial impact of the OBBBA provisions and increased CMS audit activities.
- Acquisition Integration: Evaluate the contribution of the CareBridge and Centers acquisitions to the growth in Carelon Services and Health Benefits segments.